Cardiomyocyte‐specific overexpression of FPN1 diminishes cardiac hypertrophy induced by chronic intermittent hypoxia
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Ji-Xian Song und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang, China. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Cardiomegaly, Cation Transport Proteins, Hypoxia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Central Leading Local Science and Technology Development Fund Project, Hebei Administration of Traditional Chinese Medicine.
Abstract (Originalsprache)
The significance of iron in myocardial mitochondria function cannot be underestimated, because deviations in iron levels within cardiomyocytes may have profound detrimental effects on cardiac function. In this study, we investigated the effects of ferroportin 1 (FPN1) on cardiac iron levels and pathological alterations in mice subjected to chronic intermittent hypoxia (CIH). The cTNT‐FPN1 plasmid was administered via tail vein injection to induce the mouse with FPN1 overexpression in the cardiomyocytes. CIH was established by exposing the mice to cycles of 21%–5% FiO 2 for 3 min, 8 h per day. Subsequently, the introduction of hepcidin resulted in a reduction in FPN1 expression, and H9C2 cells were used to establish an IH model to further elucidate the role of FPN1. First, FPN1 overexpression ameliorated CIH‐induced cardiac dysfunction, myocardial hypertrophy, mitochondrial damage and apoptosis. Second, FPN1 overexpression attenuated ROS levels during CIH. In addition, FPN1 overexpression mitigated CIH‐induced cardiac iron accumulation. Moreover, the administration of hepcidin resulted in a reduction in FPN1 levels, further accelerating the CIH‐induced levels of ROS, LIP and apoptosis in H9C2 cells. These findings indicate that the overexpression of FPN1 in cardiomyocytes inhibits CIH‐induced cardiac iron accumulation, subsequently reducing ROS levels and mitigating mitochondrial damage. Conversely, the administration of hepcidin suppressed FPN1 expression and worsened cardiomyocyte iron toxicity injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang, China.
- Department of Physiology, Institute of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, China.
- Hebei Key Laboratory of Turbidity Toxin Syndrome, The First Affiliated Hospital Hebei University of Chinese Medicine, Shijiazhuang, China.
ORCID-Profile: Ji-Xian Song, Yashuo Zhao
Förderung
- The Central Leading Local Science and Technology Development Fund Project
- Hebei Administration of Traditional Chinese Medicine
Zitieren
APA
Song, J. X., Xu, S., Chen, Q., Gou, Y., Zhao, C. B., Jia, C. L., Liu, H., Zhang, Z., Li, B. L., Gao, Y., Zhao, Y., & Ji, E. S. (2024). Cardiomyocyte‐specific overexpression of FPN1 diminishes cardiac hypertrophy induced by chronic intermittent hypoxia. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18543
Vancouver
Song JX, Xu S, Chen Q, Gou Y, Zhao CB, Jia CL, et al. Cardiomyocyte‐specific overexpression of FPN1 diminishes cardiac hypertrophy induced by chronic intermittent hypoxia. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18543
BibTeX
@article{Song2024,
author = {Song, Ji-Xian and Xu, Shan and Chen, Qi and Gou, Yujing and Zhao, Chen-Bing and Jia, Cui-Ling and Liu, Han and Zhang, Zhi and Li, Bo-Liang and Gao, Yuhui and Zhao, Yashuo and Ji, En-Sheng},
title = {Cardiomyocyte‐specific overexpression of FPN1 diminishes cardiac hypertrophy induced by chronic intermittent hypoxia},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18543}
}
EUVIMED